Anti-Hypertensive Drugs - Thailand

Thailand

Thailand's Anti-Hypertensive Drugs market is expected to witness an impressive revenue growth in the coming years.
By 2024, the projected revenue is estimated to reach €34.17m.
This indicates a positive trend in the market, with an annual growth rate (CAGR 2024-2029) of 0.32%.
By 2029, the market volume is projected to reach €34.72m.
In comparison to other countries, United States is expected to generate the highest revenue in the global Anti-Hypertensive Drugs market.
In 2024, the revenue generated United States alone is estimated to be a staggering €11,400.00m.
This highlights the significant contribution of the United States to the overall market.
Thailand's increasing elderly population and rising prevalence of hypertension drive the demand for anti-hypertensive drugs in the country.

Key regions: Japan, India, Italy, Brazil, South Korea

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Anti-Hypertensive Drugs market has been steadily growing in Thailand over the past few years.

Customer preferences: One of the main reasons for this growth is the increasing prevalence of hypertension in the country. As the population ages and lifestyles change, more and more people are being diagnosed with high blood pressure. This has led to a greater demand for anti-hypertensive drugs, as patients seek to manage their condition and prevent further health complications.

Trends in the market: Another trend in the market is the increasing availability of generic versions of popular anti-hypertensive drugs. This has made treatment more affordable for patients, particularly those who may not have had access to expensive brand-name medications in the past. As a result, the market for generic anti-hypertensive drugs has been growing rapidly in Thailand.

Local special circumstances: There are also some unique factors that are driving the growth of the anti-hypertensive drugs market in Thailand. For example, the country has a large population of people who practice traditional medicine, and there is a growing interest in using herbal remedies to treat hypertension. This has led to the development of a number of herbal anti-hypertensive drugs that are popular among Thai consumers.

Underlying macroeconomic factors: Overall, the growth of the anti-hypertensive drugs market in Thailand can be attributed to a combination of demographic, economic, and cultural factors. As the population ages and lifestyles change, the demand for anti-hypertensive drugs is likely to continue to grow. Additionally, the increasing availability of generic medications and the popularity of traditional medicine are likely to shape the market in unique ways in the years to come.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.